Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-04-20 Audit Report / Informat…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Opinia.pdf
Audit Report / Information Classification · 100% confidence The document is titled "Sprawozdanie niezależnego biegłego rewidenta" (Independent Auditor's Report) and explicitly states it is a report on the audit of the financial statements ("Sprawozdanie z badania sprawozdania finansowego") for the period ending December 31, 2016. It details the scope of the audit, the responsibilities of management and the auditor, and concludes with an opinion ("Opinia"). This content perfectly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, distinguishing it from a full Annual Report (10-K) or an Earnings Release (ER). FY 2016
2017-04-20 Polish
Zawarcie istotnej umowy w zakresie realizacji Projektu TNBC. - Content (PL)
Regulatory Filings Classification · 85% confidence The document is a formal announcement by the Management Board ('Zarząd') of GLG Pharma S.A. detailing the signing of a cooperation agreement ('umowa o współpracy') with the Pharmaceutical Institute regarding the development of a targeted therapy for triple-negative breast cancer (Project TNBC). It outlines the scope of work, deliverables (synthesis of active substance GLG-805 under GMP, documentation preparation), timelines, contract value (984 thousand PLN gross), and payment structure based on milestones/reports. This type of announcement, concerning a significant business development, contract signing, or strategic partnership, does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (AGM-R, DVA), or insider trading (DIRS). It is a material business event announcement. Since there is no specific category for 'Material Business Contract Announcement' or 'R&D Collaboration Agreement', and it is not a general regulatory filing (RNS) or a presentation (IP), the closest fit among the provided options that covers significant business/financing activities is 'Capital/Financing Update' (CAP) if the contract is seen as securing future development funding/milestones, or 'Regulatory Filings' (RNS) as a general catch-all for material non-financial news. Given the focus is on a specific R&D contract and its financial implications, and lacking a better fit, 'RNS' (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a material, non-standard announcement.
2017-04-06 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów w GLG Pharma S.A. - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document is a formal notification ('zawiadomienie') from Apollo Capital entities to GLG Pharma S.A. regarding a change in their direct and indirect shareholding percentage in the company's general meeting votes. This notification explicitly references Article 69 of the Polish Public Offering Act, which governs notifications of changes in significant share ownership thresholds. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document details the exact number of shares acquired and the resulting percentage change in voting rights for both entities involved.
2017-04-03 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów w GLG Pharma S.A. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a formal notification from Quark Ventures S.A. to GLG Pharma S.A. regarding a change in the percentage of voting rights held in the General Meeting (Walne Zgromadzenie - WZ). The notification explicitly references Article 69 of the Polish Public Offering Act, which mandates reporting when ownership thresholds (5%, 10%, 15%, 20%) are crossed due to share transactions. This type of filing, reporting changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document details the 'before' and 'after' shareholding percentages and the transaction that caused the change.
2017-03-14 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów w GLG Pharma S.A. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a formal notification from Quark Ventures LLC to GLG Pharma S.A. regarding a change in its shareholding percentage in the company's General Meeting (Walne Zgromadzenie - WZ). The text explicitly mentions the legal basis (Art. 69 of the Polish Public Offering Act) and details the crossing of ownership thresholds (5%, 10%, 15%, and 20%) due to the sale of shares. This type of filing, reporting changes in significant share ownership that cross statutory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (2424 chars), but it is the primary notification itself, not an announcement of a report, thus MRQ is the correct classification over RPA/RNS.
2017-03-10 Polish
Wykaz akcjonariuszy dysponujących co najmniej 5% głosów na Nadzwyczajnym Walnym Zgromadzeniu Spółkiw dniu8lutego 2017 r. - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (505 characters) and appears to be a regulatory disclosure in Polish, referencing Article 70, Section 3 of the Public Offering Act ('Ustawa o ofercie publicznej'). It specifically details the voting results and major shareholder information from an Extraordinary General Meeting ('Nadzwyczajnym Walnym Zgromadzeniu') held on February 8, 2017, identifying Glatton Sp. z o.o. as holding 66.67% of the votes. This content directly relates to the official results of a shareholder vote. The most fitting category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a full report, nor is it a general announcement about a report's publication (RPA/RNS), but rather the specific result itself.
2017-02-10 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.